PD Dr. Fabian Müller

Medizinische Fakultät Department of Medicine 5 – Haematology and Oncology Professur für CAR-T-Zell-Therapie

Human CD22-transgenic, primary murine lymphoma challenges immunotherapies in organ-specific tumor microenvironments (2021) Gsottberger F, Brandl C, Wendland K, Petkovic S, Emmerich C, Erber R, Geppert CI, et al. Journal article Purification and functional characterization of CD34(+) cells from cryopreserved apheresis products of patients with bone marrow infiltrating malignancies (2021) Wendland K, Petkovic S, Aigner M, Strobel J, Mackensen A, Müller F Conference contribution Synergy of simultaneous activation of cell death pathways of unfolded protein response and of protein synthesis inhibition converges at IRE1a-immunotoxins generate a therapeutic window (2021) Gsottberger F, Meier C, Ammon AM, Petkovic S, Mellenthin L, Krumbholz M, Metzler M, et al. Conference contribution The EMT transcription factor ZEB1 blocks osteoblastic differentiation in bone development and osteosarcoma (2021) Ruh M, Stemmler M, Frisch I, Fuchs K, van Roey R, Kleemann J, Roas M, et al. Journal article Neue antikörperbasierte Therapien in der Hämatologie (2021) Müller F Journal article, Review article Triton X-114 and Amine-Based Wash Strategy Reduces Lipopolysaccharides to FDA Limit and Achieves Purer, More Potent Recombinant Immunotoxin (2021) George R, Gsottberger F, Ammon AM, Wendland K, Mellenthin L, Mackensen A, Müller F Journal article A murine, myc-driven lymphoma model expressing human CD22 enables testing of targeted therapies and their effects on tumor immune microenvironment (2020) Gsottberger F, Brandl C, Petkovic S, Emmerich C, Nitschke L, Mackensen A, Müller F Conference contribution Blocking counter regulation of unfolded protein response by targeted protein synthesis inhibition produces highly synergistic cell death in several cancer entities (2020) Müller F, Gsottberger F, Meier C, Petkovic S, Krumbholz M, Metzler M, Mackensen A Conference contribution A human CD22 transgenic, myc-driven lymphoma model to test effects of targeted therapies on lymphoma immune microenvironment in immunecompetent mice (2019) Wagner F, Brandl C, Petkovic S, Emmerich C, Nitschke L, Mackensen A, Müller F Conference contribution 2-Deoxyglucose induced unfolded protein response enhances efficacy of immunotoxin Moxetumomab pasudotox against lymphoma and leukemia xenografts (2019) Wagner F, Meier C, Krumbholz M, Metzler M, Mackensen A, Müller F Conference contribution